Loading patent…
AssigneesElectrophoretics Limited, King's College London
InventorsSimon Harold Lovestone, Andreas Christian Güntert, James Campbell, Helen Louise Byers, Darragh P.W. O'Brien
Estimating the term…
The invention provides a method for aiding the diagnosis or prognostic monitoring of Alzheimer's disease in a subject, said method comprising; providing a sample of blood obtained from said patient; assaying the amount of gelsolin present in said sample; comparing the amount of gelsolin present in said sample to a reference amount of gelsolin present in a sample from a healthy subject, wherein detection of a gelsolin level in the sample from said patient which is lower than the gelsolin level in the reference sample indicates an increased likelihood of Alzheimer's disease in said patient. Other markers are C1 protease inhibitor and ceruloplasmin. Both blood samples and tissue samples have been investigated.
A method for aiding the diagnosis of Alzheimer's disease in a subject, said method comprising;
A method for aiding the diagnosis or prognostic monitoring of Alzheimer's disease in a subject, said method comprising;
A method for aiding the diagnosis or prognostic monitoring of Alzheimer's disease in a subject, said method comprising;
16-19. (canceled)
An assay device for use in the diagnosis of Alzheimer's disease, which comprises a solid substrate having a location containing a material, which recognizes, binds to, or has affinity for a polypeptide, or a fragment, variant or mutant thereof, wherein the polypeptide is selected from gelsolin (SEQ ID NO:1), C1 protease inhibitor (SEQ ID NO:2), or Ceruloplasmin (SEQ ID NO:3).
A kit for use in the detection of gelsolin polypeptide, said kit comprising one or more of the following peptides of Table B:
A kit for use in the diagnosis of Alzheimer's disease, comprising one or more of the following peptides of Table B:
31-33. (canceled)
A method of determining the APOE ε4 genotype of a subject, said method comprising assaying the C1 protease inhibitor level in a sample of blood from said subject.
A method of predicting the age of onset of Alzheimer's disease for a subject, said method comprising assaying the ceruloplasmin levels in a sample of blood from said subject.
(canceled)
Dependencies are inferred from the claim text.